VR Logo

MaxCyte Inc. (MXCT) download report


Healthcare | Diagnostics Services

MaxCyte Inc. (MXCT) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies.

IPO Date: 30-Jul-2021

Founder, Pres, CEO & Exec. Director: Mr. Douglas Arthur Doerfler

Chief Financial Officer: Mr. Ronald Evan Holtz CPA, Ph.D.

Listing: NASDAQ: MXCT

Country: United States

Headquarters: Gaithersburg, MD

Website: https://maxcyte.com

Key Facts

Market cap: $510.75 Mln

Revenue (TTM): $38.99 Mln

Earnings (TTM): $-16.04 Mln

Cash: $246.28 Mln

Total Debt: $13.25 Mln

Insider's Holding: 5.22%

Liquidity: Low

52 Week range: $3.36 - 17.44

Shares outstanding: 101,540,000

5 Years Aggregate:

  • CFO: $-48.43 Mln
  • EBITDA: $-57.31 Mln
  • Net Profit: $-62.58 Mln

Stock Performance

Time Period MaxCyte (MXCT) S&P BSE Sensex* S&P Small-Cap 600*
YTD-50.64-8.74-17.60
1 month9.11-2.01-5.38
3 months-29.85-7.32-13.22
1 Year--0.45-16.83
3 Years--10.327.77
5 Years--11.296.21
10 Years--12.1410.48
As on 24-Jun-2022 *As on 27-Jun-2022